Compare Dyne Therapeutics Inc. Common Stock (DYN) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs 3M Company — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while 3M Company trades at $164.75 (market cap $83.94B). The key difference: 3M Company is far larger — about 29.3× Dyne Therapeutics Inc. Common Stock's market cap, and 3M Company pays a 1.92% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and 3M Company for 169 Days on average.
| DYN | MMM | |
|---|---|---|
Market Cap | $2.86B | $83.94B |
Volume | 3,341,579 | 2,547,210 |
Sector | Health | Industrials |
52-Week High | $26.78 | $183.79 |
52-Week Low | $14.60 | $141.10 |
Typical Hold Time | 0 Days | 169 Days |
Enterprise Value | $2.18B | $93.17B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
3M (MMM) trades at $164.46, up 2.22% with strong recent earnings beats and a bullish analyst consensus price target of $191. The stock shows bearish technical signals but maintains solid fundamentals with 11.9% net margins and 82.77% ROE. Recent Q2 2026 results confirmed operational improvements with 5.4% organic growth and raised guidance, though technical indicators suggest near-term pressure.
The outlook remains positive with manageable litigation risks and strategic focus on high-growth areas like data centers. Key risks include consumer segment weakness and debt levels. Wall Street sentiment is balanced with 48% buy ratings, supporting potential upside from current levels despite technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
